Elixxer

Elixxer FCF/Debt

The Free Cash Flow to Debt Ratio of Elixxer (ELXR.H.V) as of Oct 25, 2026 is -24.84 %. In the previous year, Free Cash Flow to Debt Ratio was -37.66 % — a change of -34.05% (higher).

FCF/Debt

-24.84 %

YoY

-34.05%

Last updated:

Free Cash Flow to Debt Ratio of Elixxer is 2023 -24.84 % . Free Cash Flow to Debt Ratio of Elixxer was 2022 -37.66 % . It decreases by -34.05% higher compared to the previous year.

The Elixxer FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2017
-817.45 CAD
Jan 1, 2018
-182.49 CAD
Jan 1, 2019
-97.18 CAD
Jan 1, 2020
-23.01 CAD
Jan 1, 2021
-61.41 CAD
Jan 1, 2022
-37.66 CAD
Jan 1, 2023
-24.84 CAD
The Elixxer FCF/Debt history
YEARFCF/DebtYoY
-24.84 %-34.05%
-37.66 %-38.67%
-61.41 %+166.85%
-23.01 %-76.32%
-97.18 %-46.75%
-182.49 %-77.68%
-817.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Elixxer Stock analysis

What does Elixxer do? Elixxer Ltd. invests in cannabis-related businesses licensed for cultivation, production, and sale of cannabis and cannabis-derived products. The company focuses on medical cannabis and specialty pharmaceutical products, growing and producing medical-grade cannabis for global markets. Its brands include Viridi, Easyjoint, Freia, Little Green Pharma (LGP), and One Premium Cannabis, which are used for CBD cosmetics, natural wellness products, and pharmaceutical applications. Elixxer targets medical and wellness segments through its subsidiaries in Australia, Canada, Switzerland, Italy, and Jamaica, where it operates cultivation, extraction, and production facilities for legal cannabis products. The company generates revenue through its portfolio of cannabis investments, including nutraceutical, cosmetics, and pharmaceutical segments. Its subsidiaries LGC Finance Limited, LGC Capital EU OU, and LGC Capital Spain S.L. support its global operations, while its brands cater to consumers seeking CBD-based wellness solutions and medical cannabis products. Elixxer's focus on medical cannabis and pharmaceutical applications drives its market positioning in the global cannabis industry. Elixxer Ltd. primarily serves medical and specialty cannabis markets, with a strong emphasis on pharmaceutical-grade products. Its investments span cultivation, extraction, and production facilities across multiple countries, enabling it to supply global markets with medical cannabis and CBD-derived products. The company's brands are positioned within the wellness and pharmaceutical sectors, targeting consumers and healthcare providers interested in natural and medical cannabis solutions. Elixxer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elixxer stock

Free Cash Flow to Debt Ratio of Elixxer is -24.84 % in 2023.

Free Cash Flow to Debt Ratio of Elixxer changed from -37.66 % to -24.84 %, representing a -34.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Elixxer since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Elixxer with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Elixxer

All Key Metrics — Elixxer